Mantle Cell Lymphoma

December 17, 2020 — The European Commission has granted a conditional marketing authorization to the CD19-targeted CAR T-cell therapy KTE-X19 for use in adult patients with relapsed or refractory mantle cell lymphoma who had previously received 2 or more lines of systemic therapy including a BTK inhibitor.

Brian T. Hill, MD, PhD, discusses ​the safety profiles of BTK inhibitors in mantle cell lymphoma.

Preetesh Jain, MD, PhD, discusses the rationale to evaluate ibrutinib in combination with rituximab in mantle cell lymphoma.

December 5, 2020 - VLS-101, a novel ROR1-targeted antibody-drug conjugate, demonstrated encouraging clinical efficacy, consistent pharmacokinetics, and a favorable safety profile in patients with heavily pretreated mantle cell lymphoma and diffuse large B-cell lymphoma.

Jia Ruan, MD, PhD, discusses future research with CAR T-cell therapy in mantle cell lymphoma.

With the shift away from chemoimmunotherapy, and the adoption of novel combinations, as well as cellular therapy, the MCL treatment landscape has entered a new era. Looking forward, minimal residual disease is bound to play a critical role in terms of guiding treatment selection.

Joshua Brody, MD, discusses the expanding role of venetoclax in mantle cell lymphoma.

Brian T. Hill, MD, PhD, discusses the utility of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treatment considerations for patients with relapsed/refractory mantle cell lymphoma.

Joshua Brody, MD, discusses management strategies for the toxicities associated with CAR T-cell therapy in mantle cell lymphoma.

Alan P. Z. Skarbnik, MD, highlights how treatment decisions in mantle cell lymphoma have become more nuanced since the FDA approval of the CAR T-cell therapy brexucabtagene autoleucel in the relapsed/refractory setting.

Jia Ruan, MD, PhD, discusses treatment considerations in mantle cell lymphoma.

Alan P. Z. Skarbnik, MD, discusses treatment strategies for patients with mantle cell lymphoma.

Joshua Brody, MD, discusses advances made with CAR T-cell therapy in MCL, the promise of venetoclax in B-cell malignancies, and the potential for bispecific antibody combination regimens in this disease.

Joshua Brody, MD, discusses the potential role for bispecific antibodies in mantle cell lymphoma.

Jia Ruan, MD, PhD, discusses the evolving armamentarium ​in mantle cell lymphoma.

Joshua Brody, MD, discusses the challenges of mitigating antigen escape in mantle cell lymphoma.

Jia Ruan, MD, PhD, discusses the incidence of mantle cell lymphoma.

Alan P. Z. Skarbnik, MD, discusses the approval of brexucabtagene autoleucel in ​relapsed/refractory mantle cell lymphoma.

Brian T. Hill, MD, PhD, discusses next steps for research examining CAR T-cell therapy in mantle cell lymphoma.

Caron Jacobson, MD, discusses the approval of brexucabtagene autoleucel in mantle cell lymphoma.

Alan P. Z. Skarbnik, MD, discusses factors to consider in selecting between BTK inhibitors in mantle cell lymphoma.

Brian T. Hill, MD, PhD, discusses the impact of the coronavirus disease 2019 pandemic on patients with mantle cell lymphoma.

Brian T. Hill, MD, PhD, reflects on how the approval of CAR T-cell therapy has impacted clinical practice for his patients with MCL, ongoing research with practice-changing implications, and how MCL treatment has evolved during the coronavirus disease 2019 pandemic.

Brian T. Hill, MD, PhD, discusses the FDA approval of brexucabtagene autoleucel for patients with relapsed/refractory mantle cell lymphoma.